CytomX Therapeutics (CTMX)
(Real Time Quote from BATS)
$2.25 USD
+0.06 (2.74%)
Updated Mar 28, 2024 12:14 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CTMX 2.25 +0.06(2.74%)
Will CTMX be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for CTMX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CTMX
CytomX Therapeutics (CTMX) Lags Q4 Earnings Estimates
CytomX (CTMX) to Report Q4 Earnings: Here's What to Expect
CTMX: What are Zacks experts saying now?
Zacks Private Portfolio Services
AstraZeneca's (AZN) sBLA for Enhertu Gets FDA's Priority Tag
Apellis (APLS) Down on Negative CHMP Opinion for Pegcetacoplan
SpringWorks (SWTX) Surges More Than 80% in 3 Months: Here's Why
Other News for CTMX
CytomX Therapeutics: A Balanced Hold Rating Amidst Financial Uncertainty and Clinical Progress
CytomX Therapeutics Welcomes New Director and Updates Bylaws
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
CytomX Therapeutics appoints Zhen Su to board of directors
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas